不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
滤泡性淋巴瘤个体化治疗与预后因素的进展
英文原题：Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.
查看英文原题
Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
滤泡性淋巴瘤是最常见的惰性 B 细胞淋巴瘤，特征为疾病缓慢进展，患者可能存活数十年。总体预后通常良好，但部分患者仍有疾病进展或转化为侵袭性变异型的风险。复发/难治性滤泡性淋巴瘤治疗近期进展包括 cereblon 调节剂、激酶抑制剂、嵌合抗原受体（CAR）T 细胞疗法和抗体-药物偶联物。对新型预后标志物的持续研究，可能改善对早期进展、多次复发或组织学转化高危患者的识别，从而促进更精准、个体化的治疗策略。
展开英文摘要原文
Follicular lymphoma is the most prevalent form of indolent B-cell lymphoma, characterized by gradual disease progression and potential survival over several decades. Although the overall prognosis is typically favorable, some patients remain at risk for disease progression or transformation into a more aggressive variant.
Recent advancements in the treatment of relapsed or refractory follicular lymphoma include cereblon modulators, kinase inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and antibody-drug conjugates. Ongoing research into novel prognostic markers may improve the identification of patients at high risk for early progression, multiple relapses, or histological transformation, facilitating more precise and individualized treatment strategies.
论文信息
- 作者
- Cheng S、Liu Y
- 第一作者单位
- Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan, China.China
- 通讯作者单位
- Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, Henan, China. yyliu@zzu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Current treatment options in oncology2025 Apr
- 原文标识
- PubMed 40172809 · DOI 10.1007/s11864-025-01297-6